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Chronicheartfailure(CHF)isassociatedwithelevatedconcentrationsoftumornecrosisfactor(TNF)αandcardiotrophin-1(CT-
1) and altered peripheral blood mononuclear cell (PBMC) function. Therefore, we tested whether CT-1 induces TNFα in PBMC
of healthy volunteers. CT-1 induced in PBMC TNFα protein in the supernatant and TNFα mRNA in a concentration- and time-
dependent manner determined by ELISA and real-time PCR, respectively. Maximal TNFα protein was achieved with 100ng/mL
CT-1after3–6hoursandmaximalTNFαmRNAinductionafter1hour.ELISAdatawereconﬁrmedusingimmunoﬂuorescentﬂow
cytometry. Inhibitor studies with actinomycin D and brefeldin A showed that both protein synthesis and intracellular transport
are essential for CT-1induced TNFα expression. CT-1caused a dose dependent nuclear factor (NF)κB translocation. Parthenolide
inhibited both NFκBt r a n s l o c a t i o na n dT N F α protein expression indicating that NFκB seems to be necessary. We revealed a new
mechanism for elevated serum TNFα concentrations and PBMC activation in CHF besides the hypothesis of PBMC activation by
bacterial translocation from the gut.
Copyright © 2009 Michael Fritzenwanger et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
CHF is not only the failure of the heart to generate suﬃcient
cardiac output, but is a multisystemic disorder with immune
activation leading to increased concentrations of several
cytokines [1].
In CHF several studies showed increased concentrations
of proinﬂammatory cytokines such as TNFα, interleukin
(IL)-1, IL-6, IL-18, and cardiotrophin-1 (CT-1) [2–5]. One
of the most examined proinﬂammatory molecules in CHF
is TNFα.T N F α is a trimeric 17-kDa polypeptide mainly
produced by monocytes and macrophages. The eﬀects of
TNFα on cardiac function are concentration and time-
dependent. Short-term TNFα expression is thought to be an
adaptive mechanism; whereas prolonged expression causes
left ventricular dysfunction and cardiomyopathy leading to




family that consists of IL-6, IL-11, ciliary neurotrophic
factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like
cytokine (CLC), leukemia inhibitory factor (LIF), neuropoi-
etin (NPN), and oncostatin M (OSM) and has recently been
supplemented by the addition of two newly characterized
cytokines: IL-27 and IL-31 [7]. All these cytokines bind to a
speciﬁcreceptorchain(IL-6R,IL-11R,orLIFRforCT-1,LIF,
OSM). Following cytokine binding the cytokine/receptor
complex associates with glycoprotein 130 (gp130) causing
tyrosine phosphorylation of gp130 and the signal is trans-
duced via the Janus kinase (JAK)/signal transducer and
activation of transcription 3 (STAT3) pathway [8–10]. CT-1
is expressed in a time-dependent manner during embryoge-
nesis of organs, is expressed in the heart during life, induces2 Mediators of Inﬂammation
cardiac myocyte hypertrophy, and is able to prevent myocyte
apoptosis via a mitogen dependent kinase pathway [8, 11].
I n c r e a s e dC T - 1c o n c e n t r a t i o n sw e r ed e t e c t e di np a t i e n t s
with acute myocardial infarction and chronic heart failure
(CHF). Furthermore, CT-1 plasma concentrations correlate
with the severity of left ventricular dysfunction [11–14].
However, CT-1 has not only eﬀects on myocytes but also
on vasculature by decreasing systemic vascular resistance in
an animal model [15], by induction of acute phase proteins
in rat hepatocytes [16], and by attenuation of endotoxin-
induced acute lung injury [17].
There are several studies showing that in CHF PBMCs
produce TNFα [18, 19]. But so far the mechanisms
responsible for TNFα production in these cells under these
circumstances are not determined.
InthisstudyweinvestigatedwhetherCT-1inducesTNFα
expression in human PBMC of healthy volunteers. Further-
more, we designed inhibitor experiments to characterise the
underlying pathway.
2.MaterialsandMethods
2.1. Reagents. Recombinant human CT-1 was purchased
from R&D Systems (Wiesbaden, Germany) and dissolved
according to the manufacturer’s instruction. Actinomycin D,
brefeldin A, and parthenolide were purchased from Sigma
Chemicals (Deisenhofen, Germany). The blocking antibody
against CT-1 was purchased from R&D Systems (Wiesbaden,
Germany).
2.2. Cell Culture. Human peripheral blood mononuclear
cells were obtained from healthy volunteers by Ficoll-paque
(Amersham Bioscience, Uppsala, Sweden) centrifugation.
The cells were washed three times with PBS, resuspended
in RPMI 1640 supplemented with 10% fetal calf serum,
1% penicillin, streptomycin (all from Biochrom AG, Berlin,
Germany), and cultured in plastic dishes at 37
◦Ci n a
humiﬁed 5% CO2 atmosphere. Cells were cultivated for
24hour with RPMI 1640 supplemented with 10% fetal calf
serum, 1% penicillin, streptomycin. Afterwards, cells were
subconﬂuent and medium was replaced by fresh medium.
After 24hours, over 90% of PBMC were alive tested by
trypan blue exclusion. Stimulation and pharmacological
s t u d i e sw e r ed o n ea f t e r w a r d s .
Primary cultures from human vein endothelial cells were
purchased from PromoCell (Heidelberg, Germany). Cell
culture was done according to the manufacturer’s manual
in endothelial growth medium with 2% fetal calf serum
(EGM, PromoCell, Heidelberg, Germany). Cells were grown
to conﬂuence in collagen I coated tissue culture plastic
(Becton Dickinson, Franklin Lakes, USA). Cells were used in
the second to ﬁfth cell passages.
All stimulants, inhibitors and media were without sig-
niﬁcant endotoxin levels according to the manufacturers’
instructions.
Pharmacological agents, dissolved in fresh medium,
were added to the cells for deﬁned time intervals and
concentrations. As a control, fresh medium was added to the
cells.
Approval for this study was given by the Ethics Com-
mittee of the Friedrich Schiller University of Jena, and
subjectsgavetheirwritteninformedconsentaccordingtothe
university guidelines.
2.3. Real-Time PCR. Total RNA from cultivated PBMC was
extracted according to the RNeasy protocol (Qiagen, Hilden,
Germany). Oneμg of total RNA was reversely transcribed
into cDNA in a volume of 20μlw i t ha v i a nm y e l o m a
leukaemia virus (AMV) reverse transcriptase and oligo
dT primers (Promega, Madison, USA) according to the
manufacturers manual.
Real-time PCR measurement of TNFα cDNA was per-
formed with the Light Cycler Instrument using the Fast
Start DNA Master SYBR Green I kit (Roche Diagnostics,
Mannheim, Germany). For veriﬁcation of the correct ampli-
ﬁcation product, PCR products were analyzed on a 2%
agarose gel stained with ethidium bromide. The speciﬁc
primer for human TNFα was purchased from R&D Systems.
The ampliﬁcation program for TNFα consisted of 1 cycle of
94
◦C with a 4-minute hold followed by 40cycles of 95
◦C
with a 45-second hold, 59
◦C annealing temperature with
a 45-second hold, and 72
◦C with a 45-second hold. The
speciﬁc primer pair for GAPDH was: sense primer 5  GGG
AAG GTG AAG GTC GG 3 , antisense primer 5  TGG ACT
CCA CGA CGT ACT CAG 3 . The ampliﬁcation program
for GAPDH consisted of 1 cycle of 95
◦C with a 30-second
hold followed by 30 cycles of 95
◦C with a 5-second hold,
59
◦C annealing temperature with a 10-second hold, and
72
◦C with a 20-second hold. Each reaction (20μl) contained
2μl cDNA, 2.5mM MgCl2, 1 pmol of each primer, and
2μL of Fast Starter Mix (containing buﬀer, dNTPs, Sybr
Green dye and Taq polymerase). Ampliﬁcation was followed
by melting curve analysis to verify the correctness of the
amplicon. A negative control without cDNA was run with
every PCR to assess the speciﬁcity of the reaction. Analysis
of data was performed using Light Cycler software version
3.5. PCR eﬃciency was determined by analysing a dilution
series of cDNA (external standard curve). The identity of
the PCR product was conﬁrmed by comparing its melting
temperature (Tm) with the Tm of amplicons from standards
or positive controls. GAPDH was analyzed in parallel to each
PCRand theresulting GAPDHvalueswereused asstandards
for presentation of TNFα transcripts.
2.4. TNFα ELISA. Cultured PBMCs were treated with vari-
ous concentrations of CT-1 for various time periodes. TNFα
concentrations in the culture supernatants were determined
by ELISA (QuantiGlo, R&D Systems, Wiesbaden, Germany)
according to the manufacturer’s instructions.
2.5. EMSA. Nuclear extracts were achieved by the EpiQuik
Nuclear Extraction KIT I (Epigentek, NY, USA) according
to the manufacturer’s manual. Afterwards, protein concen-
trations of nuclear extracts were determined according to
the Bradford methode. For determination of NFκB2 μg
of nuclear proteins were used and further analyzed by gel
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Figure 1: (a) Concentration- and time-dependent expression of TNFα protein in the supernatant after incubation with CT-1. Human
PBMCswere incubated with various concentrations of CT-1and for diﬀerent periodes. After the indicated time TNFα protein concentration
was determined by a commercial available ELISA. n = 5, data are expressed as mean ± SEM.
∗P <. 05 compared to unstimulated
cells. (b) Analysis of intracellular TNFα production using immunoﬂuorescent ﬂow cytometry. Human blood was incubated with diﬀerent
concentrations of CT-1 for 6hours in the presence of brefeldin A. Afterwards erythrocytes were lysed and cells were stained with a
monoclonal antibody against CD14 FITC-conjugated and against TNFα PE-conjugated. Monocytes were gated and results are expressed
normalized to unstimlulated monocytes. n = 11, data are expressed as mean ± SEM.
∗P <. 05 compared to unstimulated cells.
suppliers manual. EMSA kits and probes were purchased
from Panomics, Redwood City, USA.
2.6. Immunoﬂuorescent Flow Cytometric Analysis of Cytokine
Production. For intracellular staining peripheral blood was
collected in lithium-heparin tubes. 100μl of blood was
added to RPMI-1640 medium including brefeldin A (ﬁnal
concentration:1μg/ml)(Sigma,Taufkirchen,Germany),and
incubated for 6hours time at 37
◦C. Next, erythrocytes
were lysed by NH4Cl. After washing with PBS/2% FCS
cells were stained with monoclonal antibodies against the
surface antigens CD3 (Coulter-Immunotech, Krefeld, Ger-
many), CD4 (Caltag, Hamburg, Germany) CD8 or CD14
(BD-Pharmingen, Heidelberg, Germany) (15 minute, RT),
followed, after a washing step, by ﬁxation with 100μl2 %
paraformaldehyde for 10 min at RT. After a wash the cells
were incubated in 100μl permeabilisation solution (0,1%
saponin and 0,1%NaN3 in PBS) together with 1μl directly
conjugated anti-TNFα antibody (BD-Pharmingen, Heidel-
berg, Germany) for 15minute at RT. Followed by a wash
with permeabilisation solution the cells were resuspended
in PBS/2% FCS and ﬂuorescence intensity was analyzed
by ﬂow cytometry (FACSCalibur, Becton-Dickinson, Hei-
delberg, Germany). For analysis regions were deﬁned by
forward scatter and side scatter as well as CD3+/CD4+-o r
CD3+/CD8+-lymphocyte populations and CD14+ monocyte
population. Data were analyzed with CellQuest Software.
2.7. Statistical Analysis. Because the amount of the cytokines
produced was diﬀerent in each experiment, the eﬀects on
TNFα production were normalized to unstimulated cells,
which were set as one. Data were analysed by nonparametric
methods to avoid assumptions about the distribution of
the measured variables. Comparisons between groups were
made with the Wilcoxon test. All values are reported as
means ± SEM. Statistical signiﬁcance was considered to be
indicated by a value of P<. 05.
3. Results
3.1. CT-1 Induces TNFα Protein and mRNA Levels in PBMC.
In the ﬁrst sets of experiments we analysed whether CT-1
is able to induce TNFα in PBMC. As shown in Figure 1(a),
CT-1 induced in a concentration-dependent manner TNFα
in the supernatant determined by a commercial available
ELISA. Maximal TNFα concentration was found after 3
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Figure 2: Concentration- and time-dependent induction of TNFα mRNA after incubation with CT-1. Human PBMCs were incubated with
various CT-1 concentrations and for various periodes. After the indicated time mRNA was determined by real-time PCR. All TNFα mRNA
expression data were normalized to GAPDH. n = 8, data are expressed as mean ± SEM.
∗P <. 05 compared to unstimulated cells.
values after 24hours, indicating that CT-1 causes only a
transient TNFα release in PBMC. In the next experiments
we determined intracellular TNFα protein in monocytes,
CD4+ and CD8+lymphocytes after stimulation with various
concentrations of CT-1 in the presence of brefeldin A using
immunoﬂuorescent ﬂow cytometry. Intracellular TNFα
determinationinCD4+ andCD8+ lymphocytesdidnotshow
an eﬀect of CT-1 on TNFα expression (data not shown).
In monocytes we found a concentration-dependent increase
of intracellular TNFα after CT-1 application (Figure 1(b)).
These results showed that CT-1 induced TNFα in PBCM
independent of culture conditions and independent of
determination methodes.
On TNFα mRNA level we found maximal mRNA
after 1hour. Afterwards TNFα mRNA decreased (Figure 2).
Blocking CT-1 by an antibody against CT-1 inhibited CT-
1 induced TNFα mRNA (data not shown) indicating that
TNFα induction is speciﬁcally caused by CT-1.
3.2. The Eﬀe c to fC T - 1o nT N F α Expression in PBMC Is
Dependent on mRNA Synthesis and Intracellular Protein
Transport. With the next experiments we addressed the
question whether TNFα protein expression is dependent
on mRNA synthesis and intracellular protein transport. In
Figure 3 it is shown that both inhibition of mRNA synthesis
by actinomycin D and intracellular protein transport by
brefeldin A were able to abolish CT-1 induced TNFα protein
induction in the supernatant. These results showed that CT-
1 was responsible for new protein synthesis of TNFα protein.
Furthermore TNFα protein was secreted into supernatant
actively.
3.3. CT-1 Induces TNFα via NFκB. As shown in Figure 4
CT-1 caused a concentration-dependent NFκB translocation
to the nucleus determined by EMSA reaching maximal
translocation with 100ng/ml CT-1.
In the next sets of experiments we used EMSA to verify
that NFκB activation was responsible for CT-1 induced
TNFα expression in PBMC. Human umbilical vein endothe-
lial cells (HUVECs) stimulated with TNFα were used as a
control. Unstimulated cells did not show signiﬁcant NFκB
protein in the nucleus; whereas CT-1 caused translocation of




























































Figure 3: After 3 hours TNFα protein was determined by ELISA
in the supernatant. CT-1 0ng/mL was set as 1. Act: actinomycin D
(5μg/mL), inhibits mRNA transcription, Bre: brefeldin (10μg/ml),
inhibits intracellular protein transport. n = 6, data are expressed as
mean ± SEM.
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Figure 4: CT-1 causes a concentration dependent increase of NFκB
activity measured by EMSA. Bands corresponding to NFκB activity
were quantiﬁed by densitometry and expressed in arbitrary units
and normalized to unstimulated PBMC. n = 7, data are expressed
as mean ± SEM.
∗P <. 05 compared to unstimulated cells.
activation, was able to inhibit NFκB translocation to the
nucleus (Figure 5).
NFκB translocation is essential for TNFα expression as
shown in Figure 6(a) and 6(b). Because parthenolide was
able to inhibit TNFα expression both on protein and mRNA
level we conclude that CT-1 not only was responsible for
NFκB translocation to the nucleus but this translocation was
responsible for TNFα expression. Using ﬂow cytometry we
found in monocytes an increase of intracellular TNFα after
CT-1 application which could be inhibited by parthenolide
(Figure 6(c)). Parthenolide alone did not show a signiﬁcant

























inhibited by parthenolide an inhibitor of NFκB activation. Human
umbilical vein endothelial cells (HUVECs) stimulated with TNFα
were used as control.
results show that CT-1 induced TNFα in PBCM independent
of culture conditions and independent of determination
methodes and NFκB seems to be essential for the eﬀect of
CT-1 on TNFα induction in PBMC.
4. Discussion
The ﬁrst result of our study is that CT-1 is able to induce
TNFα mRNA and protein in PBMC of healthy volunteers.
TNFα is increased in serum of patients with CHF
and correlates with the severity of heart failure, cachexia
[20], and clinical outcome [21]. TNFα may be involved
in progression of CHF because high levels of TNFα can
induce left ventricular dysfunction, ventricular remodelling,
cardiomyopathy, and pulmonary edema [22, 23].
Cultured human PBMC can synthesize and secrete
TNFα. In heart failure, both the heart itself and activated
monocytes are able to secrete TNFα [18, 24]. Furthermore,
the capacity of PBMC of CHF patients to secrete TNFα
is increased compared to control. Our data are in good
agreement with these former studies and in opposite to
Shimokawa et al. [25] who found decreased cytokine gen-
eration capacity of monocytes in severe heart failure after
stimulation with lipopolysaccharide.
Besides the hypothesis that in CHF the failing heart itself
is the main source of TNFα it is speculated by other groups
that activated monocytes are responsible for increased TNFα
serum concentrations. Monocytes may be activated by LPS
fromthegutbecausethebarrierfunctionofthegutbycardial
edema is disturbed and bacteria can easily translocate from
the gut lumen to the blood stream [26].
As a third possibility our data suggest at least in theory
a new mechanism for TNFα production of PBMC in heart
failure. CT-1 produced by the failing ventricle [27]i sa b l e















































































































































































in the presence of parthenolide. Afterwards cells were lysed and
TNFα mRNA expression was determined by real-time-PCR. All
TNFα mRNA expression data were normalized to GAPDH. n =
6, data are expressed as mean ± SEM.
∗P <. 05 compared to
unstimulated cells. (b) Human PBMCs were incubated with CT-1
(50 ng/ml) for 3hours in the presence of parthenolide. Afterwards
TNFα protein concentration in the supernatant was determined by
ELISA. n = 5, data are expressed as mean ± SEM and normalized
to unstimulated cells.
∗P <. 05 compared to unstimulated cells.
∗∗not signiﬁcant compared to unstimulated cells. (c) Analysis
of intracellular TNFα production using immunoﬂuorescent ﬂow
cytometry. Human blood was incubated with 50ng/ml CT-1 for 6
hours in the presence of brefeldin A and parthenolide. Afterwards
erythrocytes were lysed and cells were stained with a monoclonal
antibody against CD14 FITC-conjugated and against TNFα PE-
conjugated. Monocytes were gated and results are expressed
normalised to unstimlulated monocytes. n=6, data are expressed as
mean ± SEM.
∗P <. 05 compared to unstimulated cells,
∗∗P <. 05
compared to cells stimulated with 50ng/ml CT-1.
mechanism might also explain why TNFα may be still
elevated in CHF even after edema were treated successfully
with diuretics and the integrity of gut mucosa was restored.
Furthermore, our data support the study of Petretta et al.6 Mediators of Inﬂammation
[28] who found that TNFα is not produced by the failing
heart or the gut in patients with mild to severe heart failure.
The second result of our study is the fact that CT-1 acti-
vatestheNFκBsysteminaconcentration-dependentmanner
in PBMC of healthy volunteers. Our in vitro data are in line
with studies that found an activation of the NFκBs y s t e mi n
peripheral blood cells in CHF. Jankowska et al. reported an
activation of the NFκB system in peripheral blood leukocytes
in CHF patients measured by immuncytochemistry [29].
Siednienko et al. found an augmented activation of NFκB
activation in blood mononuclear cells using electromobility
shift assay in patients with CHF compared to healthy
controls [30]. The exact pathway responsible for NFκB
activation in CHF is still unknown and remains to be
determined.
Our study has several limitations. We only used inhibitor
experiments to characterise the pathway responsible. Fur-
thermoreweusedarelativehighparthenolideconcentration.
But within 3hours, there is no cytotoxic eﬀect as shown
b yO ’ N e i l le ta l .i n[ 31]. We also used high CT-1 concen-
trations compared to concentrations reported in patients
with CHF by Ng et al. [12]. On the other hand a paper
published in 2008 [32] reported serum CT-1 concentration
in healthy controls and patients with metabolic syndrome
of about 100ng/ml. So far serum concentration of CT-1
in healthy controls and patients is a matter of discussion.
But independent of reported CT-1 serum concentration
the concentration of CT-1 should be much higher in the
myocardium which is the source of CT-1 in CHF [33].
Exact intramyocardial CT-1 concentrations are not deter-
mined so far, only mRNA and immunohistochemical studies
showed increased CT-1 in hearts of patients with CHF
[34].
In our experiments both TNFα mRNA expression and
TNFα protein production of PBMC showed a large standard
variation. First one explanation for the large standard
deviation may be a diﬀerent genetic susceptibility of PBMC
from diﬀerent persons to stimuli [35]. Second, we used the
low basal mRNA concentration as the basis of normalization
explaining the large standard variation. Third, the fact
that the increase of TNFα mRNA expression after CT-1
application is much higher compared to the increase of
protein in the supernatant may be explained methodically.
We used PBMC of healthy volunteers to examine the
eﬀect of CT-1 in CHF. Because in CHF many proinﬂam-
matory cytokines are elevated and PBMC are activated, it is
not easy to study the eﬀect of a single cytokine in PBMC
of patients with CHF. For this reason we used PBMC from
healthy volunteers in culture and stimulated them with
recombinant CT-1.
In conclusion, our study oﬀers a new mechanism of
increased serum TNFα concentrations in heart failure.
Interestingly, in our study LPS is not needed for elevated
TNFα expression in PBMC. Elevated TNFα concentrations
may be important in the pathogenesis and perpetuation of
heart failure by modulating systemic metabolism, causing
apoptosis and having a negative inotropic eﬀect [36]. In the
light of our results modulating CT-1 may be an interesting
pharmacological target in the treatment of CHF.
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